#DidYouKnow that there were approximately 2.4 million documented cases of lung cancer globally, with Non-Small Cell Lung Cancer (NSCLC) accounting for 2.1 million cases? Since 2019, more than 5,000 NSCLC clinical trials have been initiated globally. The Asia-Pacific region leads with 41%, followed by North America at 32%, Europe at 19%, and the rest of the world at 8%. This comprehensive report provided by the Novotech analyst team is free of charge. Want to learn more? Download the latest report. https://lnkd.in/dw9C4Fhm #NSCLC #ClinicalResearch #Novotech
Novotech’s Post
More Relevant Posts
-
Why is it critical to wait for biomarker results in non-small cell lung cancer (#NSCLC) and what challenges and issues does it create? Check out the latest discussion featuring International Association for the Study of Lung Cancer’s Stephen Liu and esteemed guests https://hubs.ly/Q02F26kn0
To view or add a comment, sign in
-
November was #lungcancerawarenessmonth, but months passing by shouldn't take away our motivation to find more effective and less toxic treatments for people affected by this condition. These are the first results of #AFM24 in NSCLC, and I feel incredibly proud to work with a team that has this "mantra" in mind (more effective but also less toxic), puts patients first, and wakes up every day willing to abate this disease. #innateimmunity #immunotherapy #oncology #clinicaltrials #clinicalresearch #NSCLC
Following our earlier promising #ASH23 update, we are also pleased to announce positive data for our innate cell engager (ICE®) #AFM24 in combination with the PD-L1 checkpoint inhibitor atezolizumab, in heavily pretreated EGFR-Wildtype Non-Small Cell Lung Cancer (#NSCLC) patients. We are encouraged by these promising results, especially considering that patients in this setting are often left without viable treatment options. We will be hosting a webcast today, December 11 at 1:30 p.m. PST / 4:30 p.m. EST / 10:30 PM CET, to discuss the data in more detail. You can read the full press release at: https://lnkd.in/dJXhGpdk
To view or add a comment, sign in
-
👩⚕️ “𝗖𝗹𝗼𝘀𝗲 𝘁𝗵𝗲 𝗖𝗮𝗿𝗲 𝗚𝗮𝗽: 𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗗𝗲𝘀𝗲𝗿𝘃𝗲𝘀 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲” 🙏 Lung cancer is the most common cancer and the leading cause of cancer death across the world, killing around 1.6 million people every year. To align with this year’s theme for 𝗪𝗼𝗿𝗹𝗱 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆, I explored which countries have the highest and lowest access to clinical trials for lung cancer. This clinical trial intelligence has been brought to you by 𝗧𝗔 𝗦𝗰𝗮𝗻, Anju Software’s clinical intelligence solution. 📊 #LungCancer #WLCD #WLCD24 #LivingWithLungCancer #ClinicalResearch #ClinicalTrials #DataScience #TAScan ##ClinicalOperations #DrugDevelopment
To view or add a comment, sign in
-
We are delighted to announce our involvement in Rewriting Cancer, a series produced for UICC by BBC StoryWorks Commercial Productions. This unique project examines the complexity of cancer and the changes in treatments that are required to achieve better outcomes for patients. Watch and learn how we and the other participants are Rewriting Cancer. In oncology we all share a common goal to improve the lives of patients. You can watch the series here if you're in the UK: https://lnkd.in/eUsRSAyi or, click here if you're outside the UK: https://lnkd.in/e89fpS3A #RewritingCancer #Cancer #OncologyInnovation, #CancerResearch #EllipsesPharma, #PrecisionMedicine, #ClinicalTrials #biotech #DrugDevelopment #OncologyDrugDevelopment
Discover the series, streaming now
To view or add a comment, sign in
-
Our Lung Cancer Screening Registry serves to help increase early lung cancer detection. Ella Kazerooni, MD, MS, FACR, and Ben Wandtke, MD, MS, highlight an opportunity to expand the registry in the latest #VoiceofRadiology blog. (🔗 in comments)
To view or add a comment, sign in
-
This content is intended for U.S. Healthcare Providers. Antibody-drug conjugates #ADCs are one emerging class of therapy in advanced or metastatic NSCLC. Explore the fundamentals of ADCs as a therapeutic approach with lung cancer experts. Watch the Cancer Conversations now at ADCevolution: https://lnkd.in/dwejCexp Reference: Coleman, N et al. NPJ Precis Oncol.2023;7(1):5.
To view or add a comment, sign in
-
🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: “𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 Prof Marc Van den Eynde & Prof Eric Van Cutsem unveil new standards in HER2-Positive Gastric Cancer Treatment. This episode delves into the KEYNOTE-811 study's significant findings, demonstrating the enhanced efficacy and safety of combining pembrolizumab with trastuzumab and chemotherapy for HER2-positive gastric cancer patients. The study marks a milestone in cancer treatment, offering a beacon of hope for patients and setting new benchmarks for future therapies. 👇 Watch the full video link in the comments! #MediMix #HER2Positive #GastricCancer #OncologyInnovation
To view or add a comment, sign in
-
#WorldLungCancerDay - Are you at risk for developing lung cancer? Silver Cross offers a low-dose CT scan lung cancer screening that's quick, painless, and non-invasive. The screening can detect nodules or spots on your lung that might be early indicators of lung cancer. It takes only a few minutes to have a scan which can potentially save your life. https://lnkd.in/gASEEjmX
To view or add a comment, sign in
-
World Lung Cancer Day raises awareness of lung cancer issues and magnifies the need for more lung cancer research funding. You can learn more about this observance here: https://lnkd.in/eCWdAtKP
To view or add a comment, sign in
97,528 followers
Felix Perez, CEO Research Director
3moThat's a significant number of NSCLC cases and trials worldwide. Thanks for sharing this informative report!